Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial

San Francisco (ots/PRNewswire) -

- Independent Study of 1,800 Patients Affirms Outstanding
Performance of XIENCE V vs. TAXUS Liberte

Late-breaking data presented today from the COMPARE trial
demonstrated that Abbott's (NYSE: ABT) market-leading XIENCE V(R)
Everolimus Eluting Coronary Stent System demonstrated significantly
better outcomes in key safety and efficacy measures compared to the
TAXUS(R) Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS). At
one year, XIENCE V demonstrated a significantly lower incidence of
major adverse cardiac events (MACE) compared to TAXUS (6.2% XIENCE V
vs. 9.1% TAXUS, p-value= 0.023) in the trial's primary endpoint,
which is a composite of all death, non-fatal heart attack (myocardial
infarction) and target vessel revascularization (TVR). Additionally,
XIENCE V demonstrated a significantly lower rate of stent thrombosis
compared to TAXUS (0.7% XIENCE V vs. 2.6% TAXUS, p-value=0.002), a
significantly lower rate of TVR (2.4% XIENCE V vs. 6.0% TAXUS,
p-value=0.0001), and a significantly lower rate of TLR (1.7% XIENCE V
vs. 4.8% TAXUS, p-value=0.0002).

The results from the COMPARE trial were presented by Peter Smits,
M.D., of Maasstad Ziekenhuis, Rotterdam, the Netherlands, during the
2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in
San Francisco.

"The COMPARE trial, which studied a real-world, complex patient
population, reaffirms what we saw in SPIRIT IV earlier today and what
we've seen throughout our SPIRIT family of trials - with XIENCE V
showing consistent, outstanding performance compared to TAXUS,
whether it's TAXUS Express in SPIRIT IV or now TAXUS Liberte in the
investigator-initiated study COMPARE," said John Capek, Ph.D.,
executive vice president, Medical Devices, Abbott.

About XIENCE V

XIENCE V is used to treat coronary artery disease by propping
open a narrowed or blocked artery and releasing the drug, everolimus,
in a controlled manner to prevent the artery from becoming blocked
again following a stent procedure. XIENCE V is built upon Abbott's
market-leading bare metal stent, the MULTI-LINK VISION(R) Coronary
Stent System. The VISION platform is designed to facilitate ease of
delivery, making it easier for physicians to maneuver the stent and
treat the diseased portion of the artery.

The XIENCE V stent is available on both over-the-wire (OTW) and
rapid exchange (RX) delivery systems. Rapid exchange is the most
widely used type of delivery system because it provides physicians
additional flexibility to work as single operators during stent
procedures.

Abbott's market-leading XIENCE V drug eluting stent is
commercially available in the United States, Europe and other
international markets. XIENCE V is an investigational device in Japan
and is currently under review by Japan's Ministry of Health, Labour
and Welfare and the Pharmaceuticals and Medical Devices Agency.

Abbott also supplies a private-label version of XIENCE V to
Boston Scientific called the PROMUS(R) Everolimus-Eluting Coronary
Stent System. PROMUS is designed and manufactured by Abbott and
supplied to Boston Scientific as part of a distribution agreement
between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation
signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis
for use on its drug eluting stents. Everolimus has been shown to
inhibit in-stent neointimal growth in the coronary vessels following
stent implantation, due to its anti-proliferative properties.

XIENCE V is indicated for improving coronary luminal diameter in
patients with symptomatic heart disease due to de novo native
coronary artery lesions (lesions less than or equal to 28 mm) with
reference vessel diameters of 2.5 mm to 4.25 mm. Additional
information about XIENCE V, including important safety information,
is available online at www.xiencev.com or
www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's
leading vascular care businesses. Abbott Vascular is uniquely focused
on advancing the treatment of vascular disease and improving patient
care by combining the latest medical device innovations with
world-class pharmaceuticals, investing in research and development,
and advancing medicine through training and education. Headquartered
in Northern California, Abbott Vascular offers a comprehensive
portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to
the discovery, development, manufacture and marketing of
pharmaceuticals and medical products, including nutritionals, devices
and diagnostics. The company employs more than 72,000 people and
markets its products in more than 130 countries.

Abbott's news releases and other information are available on the
company's Web site at www.abbott.com.

ots Originaltext: Abbott Laboratories
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media, Jonathon Hamilton, +1-408-624-0314, or Jennie Kim,
+1-408-332-4176, or Financial, John Thomas, +1-847-938-2655, or Tina
Ventura, +1-847-935-9390, all of Abbott